---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025248"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:57:56.249956+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025

## Summary
- Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.
- Schilke was previously CFO at Revance Therapeutics (2018-2025) and Achaogen.
- Base salary $540,000; target bonus 40% of salary; inducement grant of 52,000 RSUs and option for 80,000 shares.
- Marc Wilson's departure was previously announced in August 2024 for personal reasons.

## SEC filing metadata
- accession: 0000950170-25-025248
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/0000950170-25-025248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/crnx-20250221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025248
- JSON: https://secwatch.observer/filing/0000950170-25-025248.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025248.txt

## Key facts
- Executive change
  Tobin "Toby" Schilke was appointed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017025025248/0000950170-25-025248-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.